Imipenem/Cilastatin/Relebactam

  • TRADE NAME: Recarbrio (MSD)
  • INDICATIONS: Patients 18 years of age and older who have limited, or no alternative treatment options, for the treatment of the following infections caused by susceptible gram-negative bacteria: complicated urinary tract infections, including pyelonephritis; complicated intra-abdominal infections
  • CLASS: Antibiotic, Antibiotic; carbapenem (imipenem), Antimicrobial, Beta-lactamase inhibitor (relebactam), Renal dehydropeptidase inhibitor (cilastatin)
  • HALF-LIFE: 1 hour (imipenem); 1.2 hours (relebactam); 1 hour (cilastatin)

FDA APPROVAL DATE: 07/16/2019

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Ganciclovir, Valproic Acid

PREGNANCY CATEGORY: N/A
Insufficient human data to establish whether there is a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with imipenem, cilastatin, or relebactam in pregnant women.

Our database has 13 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top